Noribogaine reduces nicotine self-administration in rats

Journal of Psychopharmacology

Volumn 29, Issue 6, 2015, Pages 704-711

  Chang, Qing ^a   Hanania, Taleen ^a   Mash, Deborah C ^b,c   Maillet, Emeline L ^b  

^a PSYCHOGENICS INC   (United States)

^b Life Science and Technology Park   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

addiction; Food self administration; 3 4 nicotinic acetylcholine receptor antagonist; 7 nicotinic acetylcholine receptor antagonist

Indexed keywords

NICOTINE TARTRATE; NORIBOGAINE; SODIUM CHLORIDE; VARENICLINE; IBOGAINE; NICOTINE; NICOTINIC RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELF ADMINISTRATION; LATIN SQUARE DESIGN; MALE; NICOTINE SELF ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING CESSATION; TOBACCO DEPENDENCE; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANIMAL; DOSE RESPONSE; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; TOBACCO USE DISORDER;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; IBOGAINE; MALE; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SELF ADMINISTRATION; SMOKING CESSATION; TOBACCO USE DISORDER; VARENICLINE;

EID: 84930671705     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115584461     Document Type: Article

References (52)

1. Albuquerque EX, Pereira EF, Alkondon M, et al. Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol Rev. 2009 ; 89: 73-120
2. Alper KR, Lotsof HS, Frenken GM, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999 ; 8: 234-242
3. Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009 ; 104: 133-139
4. Badio B, Padgett WL, Daly JW. Ibogaine: A potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol Pharmacol. 1997 ; 51: 1-5
5. Baldwin PR, Alanis R, Salas R. The role of the habenula in nicotine addiction. J Addict Res Ther. 2011 ; 2: 2-11
6. Banks ML, Negus SS. Preclinical determinants of drug choice under concurrent schedules of drug self-administration. Adv Pharmacol Sc. 2012 2012 ;: 1-17
7. Baumann MH, Pablo J, Ali SF, et al. Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. Alkaloids Chem Biol. 2001a ; 56: 79-113
8. Baumann MH, Rothman RB, Pablo JP, et al. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther. 2001b ; 297: 531-539
9. Benowitz NL. Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009 ; 49: 57-71
10. Besson M, David V, Suarez S, et al. Genetic dissociation of two behaviors associated with nicotine addiction: Beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. Psychopharmacology (Berl). 2006 ; 187: 189-199
11. Bocher DPM, Naranjo C. Nouveau médicament agissant au niveau du système nerveux central utilisable dans les traitements psychothérapiques et comme antidrogue.. 1969 ;:
12. Changeux JP. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat Rev Neurosci. 2010 ; 11: 389-401
13. Chatterjee S, Steensland P, Simms JA, et al. Partial agonists of the alpha3beta4∗ neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology. 2011 ; 36: 603-615
14. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 ; 48: 3474-3477
15. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat. 2012 ; 43: 303-312
16. Freedlander J. Ibogaine: A novel anti-addictive compound. J Drug Addict Educ Erad. 2003 ; 1: 79-98
17. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999 ; 288: 88-92
18. Glick SD, Kuehne ME, Maisonneuve IM, et al. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res. 1996 ; 719: 29-35
19. Glick SD, Maisonneuve IM, Szumlinski KK. 18-Methoxycoronaridine (18-MC) and ibogaine: Comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci. 2000 ; 914: 369-386
20. Glue P, Lockhart M, Lam F, et al. Ascending-dose study of Noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015 ; 55: 189-194
21. Goutarel R, Golnhoffer N, Siddens R. Pharmacodynamics and therapeutic applications of Iboga and Ibogaine (Translated from French by Gladstone WJ). Psychedelic Monogr Essays. 1993 ; 6: 70-111
22. Hendrickson LM, Guildford MJ, Tapper AR. Neuronal nicotinic acetylcholine receptors: Common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 ; 4: 29
23. Higgins GA, Silenieks LB, Rossmann A, et al. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: Relationship to feeding behavior and impulse control. Neuropsychopharmacology. 2012 ; 37: 1177-1191
24. Improgo MR, Scofield MD, Tapper AR, et al. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: Dual role in nicotine addiction and lung cancer. Prog Neurobiol. 2010 ; 92: 212-226
25. Kenna GA, Nielsen DM, Mello P, et al. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs. 2007 ; 21: 213-237
26. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001 ; 24: 97-129
27. Levin ED, Petro A, Rezvani AH, et al. Nicotinic alpha7- or beta2-containing receptor knockout: Effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res. 2009 ; 196: 207-213
28. Lowinson JH, Ruiz P, Millman P, et al Substance Abuse: A Comprehensive Textbook. 1997 ) Substance Abuse: A Comprehensive Textbook. 3rd ed. Philadelphia, PA: Williams & Wilkens. Philadelphia, PA: Williams & Wilkens ; 1997 :
29. Maciulaitis R, Kontrimaviciute V, Bressolle FM, et al. Ibogaine, an anti-addictive drug: Pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol. 2008 ; 27: 181-194
30. Maillet EL, Milon N, Fishback J, et al. Noribogaine is a G protein-biased κ-opioid receptor agonist (submitted manuscript).. 2015a ;:
31. Maillet EL, Milon N, Heghinian MD, et al. Noribogaine inhibits alpha 7 and Alpha 3-containing neuronal nicotinic acetylcholine receptors (submitted manuscript).. 2015b) ;:
32. Mash DC, Staley JK, Baumann MH. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 1995a ; 57: PL45-50
33. Mash DC, Staley JK, Pablo JP, et al. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci Lett. 1995b ; 192: 53-56
34. Mash DC, Schenck S. Preclinical screening of an ibogaine metabolite (noribogaine) on cocaine-induced hyperlocomotion and cocaine self-administration. Soc Neurosci Abstr. 1996 1929 ; 22 :
35. Mash DC, Kovera CA, Buck BE, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci. 1998 ; 844: 274-292
36. Mash DC, Kovera CA, Pablo J, et al. Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000 ; 914: 394-401
37. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 ; 70: 801-805
38. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 2011 ) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press. Washington, DC: National Academies Press ; 2011 :
39. Obach RS, Pablo J, Mash DC. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998 ; 26: 764-768
40. Olsen CM. Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology. 2011 ; 61: 1109-1122
41. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998 ; 391: 173-177
42. Pickens CL, Cifani C, Navarre BM, et al. Effect of fenfluramine on reinstatement of food seeking in female and male rats: Implications for the predictive validity of the reinstatement model. Psychopharmacology (Berl). 2012 ; 221: 341-353
43. Rezvani AH, Mash DC, Hearn WL, et al. Noribogaine, a primary Ibogaine metabolite, reduces alcohol intake in P and fawn-hooded rats. Alcohol Clin Exp Res. 1995a ; 19: 15A
44. Rezvani AH, Overstreet DH, Lee YW. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol Biochem Behav. 1995b ; 52: 615-620
45. Rezvani AH, Overstreet DH, Yang Y, et al. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav. 1997 ; 58: 615-619
46. Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993 ; 18: 247-291
47. Salas R, Main A, Gangitano D, et al. Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit. Neuropharmacology. 2007 ; 53: 863-869
48. Samorini G. The Bwiti religion and the psychoactive plant Tabernanthe iboga (Equatorial Africa). Integration. 1995 ; 5: 105-114
49. Schneider AS, Nagel JE, Mah SJ. Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur J Pharmacol. 1996 ; 317: R1 - R2
50. Staley JK, Ouyang Q, Pablo J, et al. Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine. Psychopharmacology (Berl). 1996 ; 127: 10-18
51. Toll L, Zaveri NT, Polgar WE, et al. AT-1001: A high affinity and selective alpha3beta4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology. 2012 ; 37: 1367-1376
52. Vincent D, Séro I. Action inhibitrice de Tabernanthe iboga sur la cholinestérase du sérum. CR Soc Biol. 1942 ; 136: 612-614